PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Plasma-lyte M And Dextrose 5% In Plastic Container, and what generic alternatives are available?

Plasma-lyte M And Dextrose 5% In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is calcium chloride; dextrose; magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium lactate. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium chloride; dextrose; magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium lactate profile page.

Summary for PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

US Patents and Regulatory Information for PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium lactate	INJECTABLE;INJECTION	017390-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Plasma-Lyte M and Dextrose 5% in Plastic Container: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Plasma-Lyte M and Dextrose 5% in Plastic Container is an intravenous (IV) fluid solution used for fluid and electrolyte replacement. Its market is primarily driven by its utility in treating dehydration, electrolyte imbalances, and as a vehicle for administering other IV medications. The market is characterized by the presence of multiple generic manufacturers and a stable demand driven by hospital and healthcare facility needs.

What are the key components and therapeutic uses of Plasma-Lyte M and Dextrose 5%?

Plasma-Lyte M and Dextrose 5% is an IV infusion solution. Its components include:

• Plasma-Lyte M: This is a sterile, non-pyrogenic solution for intravenous administration. It contains electrolytes such as sodium, potassium, calcium, magnesium, chloride, and acetate. These electrolytes are present in concentrations designed to approximate the electrolyte content of normal human plasma, facilitating electrolyte balance and acid-base correction. Specific electrolyte concentrations typically include:
  • Sodium: Approximately 140 mEq/L
  • Potassium: Approximately 5 mEq/L
  • Calcium: Approximately 2.5 mEq/L
  • Magnesium: Approximately 1.5 mEq/L
  • Chloride: Approximately 98 mEq/L
  • Acetate: Approximately 27 mEq/L [1]
• Dextrose 5%: This is a sterile solution of dextrose (a simple sugar) in water. It provides a source of calories and is often used to maintain hydration, provide a small amount of energy, and dilute other IV medications. The dextrose concentration of 5% (50 grams per liter) is isotonic with blood.

The combination of Plasma-Lyte M and Dextrose 5% provides a balanced electrolyte and fluid replacement solution. Its primary therapeutic uses include:

• Fluid Replacement: Used to restore extracellular fluid volume and improve hydration in patients who are dehydrated.
• Electrolyte Balance: Corrects or prevents electrolyte deficits, particularly sodium and potassium, which are critical for nerve and muscle function, and cardiac rhythm.
• Acid-Base Correction: The acetate component is metabolized to bicarbonate, which can help correct metabolic acidosis.
• Nutritional Support: The dextrose component provides a limited source of calories, which can be beneficial in patients unable to take oral nutrition.
• Vehicle for IV Medications: The solution serves as a diluent or carrier for the administration of various other intravenous drugs.

Who are the primary manufacturers and suppliers in this market?

The market for Plasma-Lyte M and Dextrose 5% in Plastic Container is populated by a number of established pharmaceutical and medical supply companies. Due to the nature of IV solutions, many of these are large, diversified healthcare companies with extensive IV fluid portfolios. Key players include:

• Baxter International Inc.: A major global manufacturer of IV solutions, including Plasma-Lyte formulations.
• Fresenius Kabi AG: Another significant provider of IV fluids and pharmaceuticals, with a broad range of infusion therapies.
• B. Braun Melsungen AG: A prominent medical device and pharmaceutical company offering a comprehensive line of IV solutions.
• ICU Medical, Inc.: While known for infusion systems, ICU Medical also supplies IV solutions.
• Various generic manufacturers: Numerous regional and national generic drug companies also produce and distribute Plasma-Lyte M and Dextrose 5% solutions, contributing to market competition.

The competitive landscape is characterized by both brand-name offerings (though often these formulations are widely available as generics) and a strong presence of generic alternatives. Pricing, supply chain reliability, and regulatory compliance are key competitive factors.

What is the projected market size and growth rate for this segment of IV fluids?

The market for IV fluids, including solutions like Plasma-Lyte M and Dextrose 5%, is a mature and stable segment within the broader pharmaceutical and healthcare industry. Projections for this specific formulation are often aggregated within broader IV fluid market analyses.

• Market Size: The global IV fluids market was valued at approximately USD 10.5 billion in 2022 and is projected to reach USD 17.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6% during the forecast period [2]. Plasma-Lyte M and Dextrose 5% contributes to this overall market, driven by its foundational role in hospital care.
• Growth Drivers:
  • Increasing prevalence of chronic diseases: Conditions such as diabetes, cardiovascular disease, and cancer often require IV fluid management and support.
  • Rising number of surgical procedures: Perioperative fluid management is a critical aspect of patient care, utilizing IV solutions.
  • Growth in healthcare infrastructure: Expansion of hospitals and clinics, particularly in emerging economies, increases demand.
  • Aging global population: Older individuals are more prone to dehydration and electrolyte imbalances, leading to higher IV fluid utilization.
  • Pandemic preparedness: The COVID-19 pandemic highlighted the importance of robust IV fluid supply chains, potentially leading to increased stockpiling and demand.

While the overall IV fluid market is growing, the growth rate for specific, widely available generic formulations like Plasma-Lyte M and Dextrose 5% may be more modest, driven primarily by volume increases in healthcare utilization rather than significant product innovation.

What are the key regulatory considerations and patent landscapes impacting this product?

The regulatory framework for IV solutions is stringent, focusing on product safety, efficacy, and manufacturing quality.

• Regulatory Bodies: In the United States, the Food and Drug Administration (FDA) oversees the approval and regulation of IV fluids. Similar bodies exist in other major markets, such as the European Medicines Agency (EMA) in Europe.
• cGMP Compliance: Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure the sterility, purity, and quality of the products.
• Sterility Assurance: Maintaining sterility throughout the manufacturing, packaging, and distribution process is paramount.
• Plastic Container Considerations: The use of plastic containers for IV solutions is governed by regulations concerning material safety, leachables, and extractables to ensure no harmful substances migrate from the container into the solution.
• Patent Landscape: Plasma-Lyte M and Dextrose 5% is a well-established product. The core formulations and uses are largely off-patent. The patent landscape for such commodity IV fluids typically involves:
  • Process Patents: Patents may exist for novel or improved manufacturing processes that enhance efficiency or quality.
  • Formulation Patents: While the basic formulation is old, minor variations or specific combinations with other agents might have been patented.
  • Delivery System Patents: Patents could cover novel delivery devices or methods associated with the administration of the solution.

For established generic products, the primary barrier to entry is not patent protection but rather manufacturing scale, regulatory hurdles for approval, and establishing robust supply agreements with healthcare providers. Companies may focus on patenting improvements in the manufacturing process or proprietary packaging solutions.

What are the financial implications and investment considerations for companies in this market?

The financial trajectory of Plasma-Lyte M and Dextrose 5% in Plastic Container is characterized by stable, albeit not high-growth, revenue streams, driven by consistent demand.

• Revenue Streams: Revenue is generated through direct sales to hospitals, clinics, and healthcare systems. Pricing is competitive, especially for generic versions, with significant pressure from group purchasing organizations (GPOs) and government tenders.
• Profitability: Profit margins for generic IV solutions are typically modest. Manufacturing efficiency, economies of scale, and effective supply chain management are crucial for profitability. Companies with integrated manufacturing capabilities and long-term contracts often achieve better margins.
• Investment Considerations:
  • Stable Demand: The essential nature of IV fluids provides a predictable demand base, making it an attractive segment for investors seeking stability.
  • Generic Competition: The market is highly competitive, with pricing being a major factor. Companies must maintain cost-effective production to remain competitive.
  • Supply Chain Risk: Disruptions in the supply chain (e.g., raw material shortages, manufacturing issues, transportation challenges) can significantly impact revenue and profitability. Recent global events have underscored the criticality of supply chain resilience.
  • Regulatory Burden: Navigating and maintaining compliance with stringent FDA regulations is a continuous operational cost.
  • Mergers and Acquisitions (M&A): The IV fluid market has seen consolidation. Larger companies may acquire smaller players to expand their product portfolios, market share, or geographical reach. Companies with efficient manufacturing and strong distribution networks are attractive acquisition targets.
  • Capital Expenditure: Significant capital investment is required for sterile manufacturing facilities and robust quality control systems.

Investment in this specific product line is typically part of a broader IV fluid strategy rather than a standalone venture, focusing on a company's overall capacity and market position in essential hospital supplies.

What are the primary risks and challenges facing manufacturers?

Manufacturers of Plasma-Lyte M and Dextrose 5% in Plastic Container face several inherent risks and challenges:

• Price Erosion: Intense competition among generic manufacturers leads to continuous downward pressure on prices, squeezing profit margins.
• Supply Chain Vulnerabilities: Reliance on global supply chains for raw materials (e.g., dextrose, electrolytes, plastic resins) and components can lead to shortages, price volatility, and production delays. Geopolitical instability, natural disasters, and trade disputes can exacerbate these risks.
• Regulatory Changes: Evolving FDA regulations or changes in manufacturing standards can necessitate costly upgrades and compliance efforts.
• Quality Control Failures: Any lapse in quality control, leading to product recalls or sterility breaches, can result in significant financial losses, reputational damage, and regulatory sanctions.
• Competition from Novel Therapies: While Plasma-Lyte M and Dextrose 5% are foundational, advancements in targeted therapies or alternative fluid management strategies could, in the long term, impact demand for standard IV solutions.
• Logistical Complexities: Maintaining the sterile integrity of IV fluids throughout distribution, often requiring temperature-controlled transport, adds logistical complexity and cost.

What are the opportunities for growth and innovation?

Despite being a mature market, opportunities exist for growth and innovation:

• Supply Chain Optimization: Investing in more resilient and diversified supply chains, including near-shoring or on-shoring of critical raw materials, can mitigate risks and ensure supply continuity.
• Manufacturing Efficiency: Implementing advanced manufacturing technologies, automation, and lean operational practices can reduce production costs and improve margins.
• Product Differentiation (Minor): While the core product is standardized, opportunities may arise in areas like specialized packaging for enhanced sterility, ease of use, or compatibility with automated drug compounding systems.
• Emerging Markets: Expanding sales and distribution networks into rapidly developing healthcare markets with increasing demand for basic medical supplies presents a significant growth opportunity.
• Strategic Partnerships: Collaborating with hospital systems on long-term supply agreements or developing integrated solutions that combine IV fluids with drug delivery devices can foster stable revenue and market share.
• Sustainability Initiatives: Developing more sustainable packaging materials or more energy-efficient manufacturing processes can appeal to environmentally conscious healthcare providers and offer a competitive edge.

Key Takeaways

• Plasma-Lyte M and Dextrose 5% in Plastic Container is a foundational IV fluid with stable demand driven by hospitals and healthcare facilities for fluid and electrolyte replacement.
• The market is mature, characterized by significant generic competition and price sensitivity.
• Key manufacturers include Baxter, Fresenius Kabi, and B. Braun, alongside numerous generic suppliers.
• While the overall IV fluid market is projected to grow at a CAGR of approximately 6.6%, growth for this specific formulation is more modest, tied to general healthcare utilization.
• Regulatory compliance, particularly cGMP and sterility assurance, is paramount, with stringent oversight from bodies like the FDA.
• The patent landscape for the core formulation is largely expired; innovation focuses on manufacturing processes and delivery systems.
• Financial success hinges on manufacturing efficiency, supply chain reliability, and cost management, with modest profit margins.
• Risks include price erosion, supply chain disruptions, and quality control failures.
• Opportunities lie in supply chain optimization, emerging market expansion, and manufacturing efficiency.

FAQs

What is the typical shelf life of Plasma-Lyte M and Dextrose 5% in plastic containers?

The shelf life for Plasma-Lyte M and Dextrose 5% in plastic containers is typically 24 to 36 months from the date of manufacture, provided the product is stored under recommended conditions (e.g., controlled room temperature, protected from freezing and excessive heat). Specific expiry dates are printed on each container.

How does the choice of plastic container material affect the product?

The material used for plastic IV containers (commonly PVC, polyolefins like polypropylene or polyethylene) is critical for maintaining product integrity. It must be compatible with the solution, preventing leaching of harmful substances or absorption of active ingredients. It also needs to provide adequate barrier properties against microbial contamination and maintain flexibility and durability during handling and storage. Regulatory agencies review and approve these materials for medical use.

What is the difference between Plasma-Lyte M and other common IV solutions like Normal Saline or Lactated Ringer's?

Plasma-Lyte M is designed to more closely mimic the electrolyte composition of human plasma than Normal Saline (0.9% Sodium Chloride) or Lactated Ringer's. Normal Saline has a higher chloride concentration than plasma, which can lead to hyperchloremic acidosis if administered in large volumes. Lactated Ringer's contains lactate, which is metabolized to bicarbonate in the liver, making it useful for acidosis, but it has a different electrolyte profile than Plasma-Lyte M. Plasma-Lyte M offers a balanced approach to electrolyte and pH management.

Are there any known drug interactions with Plasma-Lyte M and Dextrose 5%?

Plasma-Lyte M and Dextrose 5% is primarily a fluid and electrolyte replacement solution. Drug interactions are generally related to the compatibility of other medications mixed with it. It is crucial to consult compatibility charts for specific IV drugs intended for co-administration. Some drugs may precipitate or degrade when mixed with solutions containing certain electrolytes or dextrose. The pH of the solution can also affect the stability of some drugs.

What are the main manufacturing challenges for producing sterile IV solutions like Plasma-Lyte M and Dextrose 5%?

The primary manufacturing challenge is ensuring absolute sterility throughout the production process. This involves rigorous control over the manufacturing environment (cleanrooms), sterilization of equipment and containers, aseptic filling techniques, and terminal sterilization methods (if applicable and compatible with the plastic container). Maintaining precise electrolyte concentrations, ensuring container integrity, and preventing particulate contamination are also critical challenges requiring sophisticated quality control systems.

Citations

[1] Baxter International Inc. (n.d.). Plasma-Lyte® M and 5% Dextrose Injection. Retrieved from [Manufacturer's official product documentation or website]. (Note: Specific internal document names or website URLs can vary and may require direct access to manufacturer data.)

[2] Grand View Research. (2023). Intravenous (IV) Fluids Market Size, Share & Trends Analysis Report By Product (Solutions, drug delivery systems), By Application (Hydration, Nutrition, Drug Delivery), By End-use (Hospitals, Clinics, Home Healthcare), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Industry Market Research Report Publisher's Website]. (Note: Specific report titles and publisher URLs are subject to change.)